NIMI
HAE icon

Natixis Investment Managers International’s Haemonetics HAE Stock Holding History

Natixis Investment Managers International’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-192
Closed -$22K – 257
2018
Q3 		$22K Sell
192
-282
-59% -$29.2K ﹤0.01% 704
2018
Q2 		$43K Buy
+474
New +$40K ﹤0.01% 706

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Natixis Investment Managers International's HAE Position: Q4 2018 in Review

Natixis Investment Managers International sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 192 shares — an estimated $22K sold.

Natixis Investment Managers International first reported a position in HAE in Q2 2018 and held it in 2 quarters. The position peaked at $43K in Q2 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

  • Natixis Investment Managers International reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
  • Natixis Investment Managers International sold 192 Haemonetics shares in Q4 2018, an estimated $22K.
  • Natixis Investment Managers International first reported a position in Haemonetics in Q2 2018 and held it in 2 quarters.
  • Natixis Investment Managers International's Haemonetics position peaked at $43K in Q2 2018.
  • 279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Natixis Investment Managers International's 13F filing for Q4 2018, filed 14 Feb 2019.